Acute success and safety of the second-generation PVAC GOLD phased RF ablation catheter for atrial fibrillation

PURPOSE: The second-generation multi-electrode catheter, pulmonary vein ablation catheter (PVAC) GOLD, was designed to improve the delivery of phased radiofrequency energy and reduce procedure times using a ‘single-shot’ approach for pulmonary vein isolation (PVI), while retaining efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Klaver, M. N., Wintgens, L. I. S., Wijffels, M. C. E. F., Balt, J. C., van Dijk, V. F., Alipour, A., Chaldoupi, S. M., Derksen, R., Boersma, L. V. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Multimedia Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925470/
https://www.ncbi.nlm.nih.gov/pubmed/32253598
http://dx.doi.org/10.1007/s10840-020-00728-8
Descripción
Sumario:PURPOSE: The second-generation multi-electrode catheter, pulmonary vein ablation catheter (PVAC) GOLD, was designed to improve the delivery of phased radiofrequency energy and reduce procedure times using a ‘single-shot’ approach for pulmonary vein isolation (PVI), while retaining efficacy and safety. This large registry presents acute success rates and safety outcomes in a daily practice setting. METHODS: A total of 1017 patients undergoing first-time ablation for atrial fibrillation (AF) using PVAC GOLD were included, 644 patients with paroxysmal AF and 373 patients with non-paroxysmal AF, divided into 175 patients receiving PVI only and 198 patients receiving PVI with additional substrate modification. RESULTS: High and comparable percentages of successful PVI could be achieved in all groups (98%, 95% and 99%; p = 0.108). The median total procedure time for all groups was 90 min [70–100]. As expected, the total procedure, ablation and fluoroscopy time were significantly longer in the PVI + substrate modification group compared with the PVI-only cases (all p < 0.001), but not between the PVI-only groups (p = 0.306, p = 0.088, p = 0.233, respectively). A total of 44 complications were observed in 43 patients (4.2%). Major complications were seen in 19 patients (1.87%) and non-major procedure–related complications were seen in 25 patients (2.46%). Complications leaving permanent sequelae were rare and occurred in only four patients (0.39%). Complications did not differ between groups (p = 0.199, p = 0.438, p = 0.240 and p = 0.465 respectively). CONCLUSION: PVAC GOLD performs successful PVI, while reducing procedure times and retaining safety for paroxysmal, persistent and long-standing persistent AF. Safety was unaffected by additional substrate modification. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10840-020-00728-8) contains supplementary material, which is available to authorized users.

Ejemplares similares